Co-Diagnostics, Inc.
CODX
Rank in Stocks
#31904
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops,... Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Share Price
$0.319
Last synced: 2026-11-09
Market Cap
$2.38M
Change (1 day)
24.22%
Change (1 year)
-97.30%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Co-Diagnostics, Inc. (CODX)
Category
Healthcare
Operating Margin for Co-Diagnostics, Inc. (CODX)
Operating Margin as of November 2026 TTM: -4,170.14%
According to Co-Diagnostics, Inc.'s latest financial reports, its current operating margin (TTM) is -4,170.14%. At the end of 2025 the company had an operating margin of -5,025.53%.
Operating Margin history for Co-Diagnostics, Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -4,170.14% | -17.02% |
| 2025 | -5,025.53% | 390.89% |
| 2024 | -1,023.75% | 63.30% |
| 2023 | -626.92% | 695.08% |
| 2022 | -78.85% | -267.55% |
| 2021 | 47.06% | -15.86% |
| 2020 | 55.93% | -102.04% |
| 2019 | -2,741.61% | -82.11% |
| 2018 | -15,328.65% | -74.27% |
| 2017 | -59,567.57% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -19,679.79% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Co-Diagnostics, Inc.'s operating margin
What is Co-Diagnostics, Inc.'s operating margin?
Co-Diagnostics, Inc.'s operating margin is -4,170.14%, as of Nov 2026.
What was Co-Diagnostics, Inc.'s operating margin in 2025?
In 2025, Co-Diagnostics, Inc.'s operating margin was -5,025.53%, compared with -1,023.75% in 2024.
How has Co-Diagnostics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Co-Diagnostics, Inc.'s operating margin was highest in 2020 (55.93%) and lowest in 2025 (-5,025.53%).
How does Co-Diagnostics, Inc.'s operating margin compare with similar companies?
Co-Diagnostics, Inc.'s operating margin (-4,170.14%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.